solid tumor News
-
T3 Pharma research project receives support by the Gebert Rüf Stiftung
The Gebert Rüf Stiftung has announced the winners of the call 2016 «Microbials – Direct Use of Micro-Organisms». Amongst the supported projects is T3 Pharma’s innovative bacteria-based cancer therapy. The applied research project takes place at the University of Basel, the results will allow T3 Pharma to expand its activities in the field of cancer treatment using ...
-
T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic
T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF. The financing was co-led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital SA, Wille Finance AG and private investors, who all ...
-
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three ...
By CervoMed
-
Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it ...
-
Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors
— With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Expanding into Chemotherapy Combination Phase 1/2 Trial — BRISBANE, CA and ST. LOUIS, MO, October 5, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the expansion of ...
-
Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that ...
-
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020
BRISBANE, CA and ST. LOUIS, MO, November 9, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020. AO-176 is an anti-CD47 antibody with a potential best-in-class profile that works by blocking the ...
-
Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
-
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors" on Thursday, April 28, 2022 at 8:00 AM EDT / 2:00 PM CET. In this fireside chat, Genenta is ...
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL™ therapy engineered with ...
-
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
Phase 1 multicenter dose-escalation and dose-expansion trial evaluating IO-202 as a monotherapy and in combination with an anti-PD-1 is initiated and expected to enroll 200 patientswith advanced solid tumors This is the second clinical trial for the IO-202 program; its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...
-
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022. The abstract, titled “Driving anti-tumor activity in solid tumors with controlled arming of allogeneic CAR-NK cells,” details the Company’s efforts to ...
-
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
SAN DIEGO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, ...
-
Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer
Buffalo, NY based Tactiva Therapeutics, Inc. announced they’ve licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) armed with a CXCR4 antibody. Pre-clinical results recently published in the Journal of Immunology (August 2018) demonstrate a potent therapeutic response with an ability to control ...
-
Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors
Multicenter Phase 1 study to evaluate IO-108 as both monotherapy and in combination with pembrolizumab in China Represents the first LILRB2-targeting antibody with IND clearance in China and the company’s fourth IND globally A Phase 1 trial evaluating IO-108 in patients with advanced solid tumors is currently enrolling in the U.S. Immune-Onc Therapeutics, Inc. ...
-
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA (pembrolizumab) in Patients with Select Solid Tumors
— With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Advancing AO-176 in Combination with Anti-PD-1 — BRISBANE, CA and ST. LOUIS, MO, February 9, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that it has entered into a clinical ...
-
Arch Oncology Secures $105 Million Series C Financing
— Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies — — Series C co-led by new investors Eventide Asset Management and Cowen Healthcare Investments alongside current investor 3×5 Partners; round includes new investors Adage Capital Management, Point72 Asset Management, Avego ...
-
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune ...
-
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 12, 2022, from 9:00 a.m. – 12:30 p.m. ET Management to Host Investor Webcast to Discuss RTX-240 Single-Agent Results in Advanced Solid Tumors and Acute Myeloid Leukemia (AML) Along with ...
-
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Immune-Onc ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you